Literature DB >> 12594515

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Edith M Janssen1, Edward E Lemmens, Tom Wolfe, Urs Christen, Matthias G von Herrath, Stephen P Schoenberger.   

Abstract

A long-standing paradox in cellular immunology concerns the conditional requirement for CD4+ T-helper (T(H)) cells in the priming of cytotoxic CD8+ T lymphocyte (CTL) responses in vivo. Whereas CTL responses against certain viruses can be primed in the absence of CD4+ T cells, others, such as those mediated through 'cross-priming' by host antigen-presenting cells, are dependent on T(H) cells. A clearer understanding of the contribution of T(H) cells to CTL development has been hampered by the fact that most T(H)-independent responses have been demonstrated ex vivo as primary cytotoxic effectors, whereas T(H)-dependent responses generally require secondary in vitro re-stimulation for their detection. Here, we have monitored the primary and secondary responses of T(H)-dependent and T(H)-independent CTLs and find in both cases that CD4+ T cells are dispensable for primary expansion of CD8+ T cells and their differentiation into cytotoxic effectors. However, secondary CTL expansion (that is, a secondary response upon re-encounter with antigen) is wholly dependent on the presence of T(H) cells during, but not after, priming. Our results demonstrate that T-cell help is 'programmed' into CD8+ T cells during priming, conferring on these cells a hallmark of immune response memory: the capacity for functional expansion on re-encounter with antigen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594515     DOI: 10.1038/nature01441

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  573 in total

1.  Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory.

Authors:  Grégoire Jeannet; Caroline Boudousquié; Noémie Gardiol; Joonsoo Kang; Joerg Huelsken; Werner Held
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 2.  Role of interleukin-21 in HBV infection: friend or foe?

Authors:  Yongyin Li; Libo Tang; Jinlin Hou
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 3.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 4.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 5.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.

Authors:  Scott N Furlan; Rajakumar Mandraju; Travis Brewer; Kole Roybal; Ty Dale Troutman; Wei Hu; Noah W Palm; Arun Unni; Chandrashekhar Pasare
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

7.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Authors:  Adam E Snook; Michael S Magee; Stephanie Schulz; Scott A Waldman
Journal:  Eur J Immunol       Date:  2014-05-21       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.